12-07-2016, 12:25 AM
Mechanisms of Cannabinoid AnalgesiaINVESTIGATOR: Ian Meng, Ph.D.
STUDY LOCATION: University of California, San Francisco
PROJECT TITLE: Mechanisms of Cannabinoid Analgesia
PROJECT TYPE: Pre-Clinical Study
STATUS: COMPLETE
RESULTS:
The full results of this study were published in <a data-ipb="nomediaparse" href="http://www.ncbi.nlm.nih.gov/pubmed/14736589">PAIN</a>. Below is a brief summary of these results.
Anecdotal evidence suggests that cannabinoid drugs, which include the main active ingredient of marijuana delta-9-tetrahydrocannabinol, may be useful for the treatment of trigeminal pain syndromes, including headache. These studies examined the effect of one cannabinoid drug, WIN 55,212-2, on the transmission of pain signals involved in head pain. The activity of pain transmission neurons in the anesthetized rat was monitored after cannabinoid administration. Results from these studies demonstrated clear inhibition of neuronal responses to noxious heat stimulation of the facial skin. In additional studies, the ability of the rat to actively withdraw from heating the face was delayed by cannabinoid drug administration. The ability of cannabinoids to delay the response to painful stimulation, combined with the demonstration of cannabinoid-induced inhibition of pain transmission signals, provides scientific evidence for a direct analgesic effect of cannabinoids.
ABSTRACT:
Cannabinoids, which include the major psychoactive ingredient in marijuana, delta-9-tetrahydrocannabinol, have a long history of use for the treatment of migraines. The mechanisms by which cannabinoids may reduce headache pain, however, remain unknown.,....
<a data-ipb="nomediaparse" href="http://www.cmcr.ucsd.edu/index.php/2015-11-20-20-52-15/completed-studies/30-mechanisms-of-cannabinoid-analgesia">http://www.cmcr.ucsd.edu/index.php/2015-11-20-20-52-15/completed-studies/30-mechanisms-of-cannabinoid-analgesia</a>
STUDY LOCATION: University of California, San Francisco
PROJECT TITLE: Mechanisms of Cannabinoid Analgesia
PROJECT TYPE: Pre-Clinical Study
STATUS: COMPLETE
RESULTS:
The full results of this study were published in <a data-ipb="nomediaparse" href="http://www.ncbi.nlm.nih.gov/pubmed/14736589">PAIN</a>. Below is a brief summary of these results.
Anecdotal evidence suggests that cannabinoid drugs, which include the main active ingredient of marijuana delta-9-tetrahydrocannabinol, may be useful for the treatment of trigeminal pain syndromes, including headache. These studies examined the effect of one cannabinoid drug, WIN 55,212-2, on the transmission of pain signals involved in head pain. The activity of pain transmission neurons in the anesthetized rat was monitored after cannabinoid administration. Results from these studies demonstrated clear inhibition of neuronal responses to noxious heat stimulation of the facial skin. In additional studies, the ability of the rat to actively withdraw from heating the face was delayed by cannabinoid drug administration. The ability of cannabinoids to delay the response to painful stimulation, combined with the demonstration of cannabinoid-induced inhibition of pain transmission signals, provides scientific evidence for a direct analgesic effect of cannabinoids.
ABSTRACT:
Cannabinoids, which include the major psychoactive ingredient in marijuana, delta-9-tetrahydrocannabinol, have a long history of use for the treatment of migraines. The mechanisms by which cannabinoids may reduce headache pain, however, remain unknown.,....
<a data-ipb="nomediaparse" href="http://www.cmcr.ucsd.edu/index.php/2015-11-20-20-52-15/completed-studies/30-mechanisms-of-cannabinoid-analgesia">http://www.cmcr.ucsd.edu/index.php/2015-11-20-20-52-15/completed-studies/30-mechanisms-of-cannabinoid-analgesia</a>